{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"21.78","value":"43.58"},{"groupId":"OG001","spread":"17.06","value":"36.41"},{"groupId":"OG002","spread":"16.53","value":"25.22"},{"groupId":"OG003","spread":"25.03","value":"39.99"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"12"},{"groupId":"OG001","value":"4"},{"groupId":"OG002","value":"13"},{"groupId":"OG003","value":"15"}],"units":"Participants"}],"title":"CYCLE 1 DAY 1"},{"categories":[{"measurements":[{"groupId":"OG002","spread":"16.27","value":"27.60"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"12"},{"groupId":"OG003","value":"0"}],"units":"Participants"}],"title":"CYCLE 1 DAY 8"}],"denoms":[{"counts":[{"groupId":"OG000","value":"12"},{"groupId":"OG001","value":"4"},{"groupId":"OG002","value":"13"},{"groupId":"OG003","value":"15"}],"units":"Participants"}],"description":"Blood samples were collected at indicated timepoints for pharmacokinetic (PK) analysis. PK parameter was determined using standard non-compartmental methods.","dispersionType":"Geometric Coefficient of Variation","groups":[{"description":"Participants with Relapsed or Refractory Multiple Myeloma (RRMM) received belantamab mafodotin as 1.9 milligram (mg)/kilogram (kg) dose on Day 1 of every alternate 28-day cycles (C1, C3, C5, C7 and so on) as a 30-60 minute infusion. Along with belantamab mafodotin, Lenalidomide (Len) was administered as 25 mg or 10 mg per oral (PO) on Days 1-21 of each 28-day cycle with 40 mg Dexamethasone (Dex) weekly PO/ intravenously (IV) on Days 1, 8, 15 and 22 of each cycle.","id":"OG000","title":"Main Study Phase: Belantamab Mafodotin 1.9mg/kg STRETCH + Len/Dex"},{"description":"Participants with RRMM received belantamab mafodotin as SINGLE full dose of 1.9 mg/kg on Day 1 of every 28-day cycle as a 30-60 minute infusion. Along with belantamab mafodotin, Lenalidomide was administered as 25 mg or 10 mg PO on Days 1-21 of each 28-day cycle with 40 mg Dexamethasone weekly PO/ IV on Days 1, 8, 15 and 22 of each cycle.","id":"OG001","title":"Main Study Phase: Belantamab Mafodotin 1.9mg/kg SINGLE + Len/Dex"},{"description":"Participants with RRMM received belantamab mafodotin as two equal divided doses of a total 2.5mg/kg dose as a 1.25 mg/kg dose on Day 1 and a 1.25 mg/kg dose on Day 8 of each 28-day cycle as a 30-60 minute infusion. Along with belantamab mafodotin, Lenalidomide was administered as 25 mg or 10 mg PO on Days 1-21 of each 28-day cycle with 40 mg Dexamethasone weekly PO/ IV on Days 1, 8, 15 and 22 of each cycle.","id":"OG002","title":"Main Study Phase: Belantamab Mafodotin 2.5mg/kg SPLIT + Len/Dex"},{"description":"Participants with RRMM received belantamab mafodotin as SINGLE full dose of 2.5 mg/kg on Day 1 of every 28-day cycle as a 30-60 minute infusion. Along with belantamab mafodotin, Lenalidomide was administered as 25 mg or 10 mg PO on Days 1-21 of each 28-day cycle with 40 mg Dexamethasone weekly PO/ IV on Days 1, 8, 15 and 22 of each cycle.","id":"OG003","title":"Main Study Phase: Belantamab Mafodotin 2.5mg/kg SINGLE + Len/Dex"}],"paramType":"GEOMETRIC_MEAN","populationDescription":"Pharmacokinetic (PK) population included all participants in all treated population from whom at least one PK sample was obtained, analyzed, and was measurable. Only those participants with data available at the specified data points were analyzed.","reportingStatus":"POSTED","timeFrame":"Pre-Dose, 0, 2 and 24 hours post-dose on Cycle 1 Day 1 and Cycle 1 Day 8","title":"Maximum Observed Concentration (Cmax) for Belantamab Mafodotin Antibody-drug Conjugate (ADC), Treatment A","type":"SECONDARY","unitOfMeasure":"Microgram/ millilitre (ug/mL)"}